Abstract
Mutations in MECP2, encoding methyl CpG-binding protein 2, cause Rett syndrome, the most severe autism spectrum disorder. Re-expressing Mecp2 in symptomatic Mecp2-null mice markedly improves function and longevity, providing hope that therapeutic intervention is possible in humans. To identify pathways in disease pathology for therapeutic intervention, we carried out a dominant N-ethyl-N-nitrosourea (ENU) mutagenesis suppressor screen in Mecp2-null mice and isolated five suppressors that ameliorate the symptoms of Mecp2 loss. We show that a stop codon mutation in Sqle, encoding squalene epoxidase, a rate-limiting enzyme in cholesterol biosynthesis, underlies suppression in one line. Subsequently, we also show that lipid metabolism is perturbed in the brains and livers of Mecp2-null male mice. Consistently, statin drugs improve systemic perturbations of lipid metabolism, alleviate motor symptoms and confer increased longevity in Mecp2 mutant mice. Our genetic screen therefore points to cholesterol homeostasis as a potential _target for the treatment of patients with Rett syndrome.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
We are sorry, but there is no personal subscription option available for your country.
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Amir, R.E. et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG–binding protein 2. Nat. Genet. 23, 185–188 (1999).
Bienvenu, T. & Chelly, J. Molecular genetics of Rett syndrome: when DNA methylation goes unrecognized. Natl. Rev. Genet. 7, 415–426 (2006).
Guy, J., Hendrich, B., Holmes, M., Martin, J.E. & Bird, A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat. Genet. 27, 322–326 (2001).
Shepherd, G.M. & Katz, D.M. Synaptic microcircuit dysfunction in genetic models of neurodevelopmental disorders: focus on Mecp2 and Met. Curr. Opin. Neurobiol. 21, 827–833 (2011).
Kavalali, E.T., Nelson, E.D. & Monteggia, L.M. Role of MeCP2, DNA methylation, and HDACs in regulating synapse function. J. Neurodev. Disord. 3, 250–256 (2011).
Guy, J., Gan, J., Selfridge, J., Cobb, S. & Bird, A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 315, 1143–1147 (2007).
Collins, A.L. et al. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum. Mol. Genet. 13, 2679–2689 (2004).
Chahrour, M. et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320, 1224–1229 (2008).
Stancheva, I., Collins, A.L., Van den Veyver, I.B., Zoghbi, H. & Meehan, R.R. A mutant form of MeCP2 protein associated with human Rett syndrome cannot be displaced from methylated DNA by notch in Xenopus embryos. Mol. Cell 12, 425–435 (2003).
St Johnston, D. The art and design of genetic screens: Drosophila melanogaster. Nature Rev. Genet. 3, 176–188 (2002).
Carpinelli, M.R. et al. Suppressor screen in Mpl−/− mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling. Proc. Natl. Acad. Sci. USA 101, 6553–6558 (2004).
Matera, I. et al. A sensitized mutagenesis screen identifies Gli3 as a modifier of Sox10 neurocristopathy. Hum. Mol. Genet. 17, 2118–2131 (2008).
Justice, M.J., Siracusa, L.D. & Stewart, A.F. Technical approaches for mouse models of human disease. Dis. Model. Mech. 4, 305–310 (2011).
Derecki, N.C. et al. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 484, 105–109 (2012).
Neuhaus, I.M. & Beier, D.R. Efficient localization of mutations by interval haplotype analysis. Mamm. Genome 9, 150–154 (1998).
Moran, J.L. et al. Utilization of a whole genome SNP panel for efficient genetic mapping in the mouse. Genome Res. 16, 436–440 (2006).
Fairfield, H. et al. Mutation discovery in mice by whole exome sequencing. Genome Biol. 12, R86 (2011).
Jurevics, H.A., Kidwai, F.Z. & Morell, P. Sources of cholesterol during development of the rat fetus and fetal organs. J. Lipid Res. 38, 723–733 (1997).
Zlokovic, B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178–201 (2008).
Gill, S., Stevenson, J., Kristiana, I. & Brown, A.J. Cholesterol-dependent degradation of squalene monooxygenase, a control point in cholesterol synthesis beyond HMG-CoA reductase. Cell Metab. 13, 260–273 (2011).
Cory, E.J., Russey, W.E. & Ortiz de Montellano, P.R. 2,3-oxidosqualene, an intermediate in the biological synthesis of sterols from squalene. J. Am. Chem. Soc. 88, 4750–4751 (1966).
Yamamoto, S. & Bloch, K. Studies on squalene epoxidase of rat liver. J. Biol. Chem. 245, 1670–1674 (1970).
Shibata, N. et al. Supernatant protein factor, which stimulates the conversion of squalene to lanosterol, is a cytosolic squalene transfer protein and enhances cholesterol biosynthesis. Proc. Natl. Acad. Sci. USA 98, 2244–2249 (2001).
Astruc, M., Tabacik, C., Descomps, B. & de Paulet, A.C. Squalene epoxidase and oxidosqualene lanosterol-cyclase activities in cholesterogenic and non-cholesterogenic tissues. Biochim. Biophys. Acta 487, 204–211 (1977).
Ingham, P.W., Nakano, Y. & Seger, C. Mechanisms and functions of Hedgehog signalling across the metazoa. Natl. Rev. Genet. 12, 393–406 (2011).
Posé, D. & Botella, M.A. Analysis of the Arabidopsis dry2/sqe1-5 mutant suggests a role for sterols in signaling. Plant Signal. Behav. 4, 873–874 (2009).
Posé, D. et al. Identification of the Arabidopsis dry2/sqe1-5 mutant reveals a central role for sterols in drought tolerance and regulation of reactive oxygen species. Plant J. 59, 63–76 (2009).
Nieweg, K., Schaller, H. & Pfrieger, F.W. Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. J. Neurochem. 109, 125–134 (2009).
Dietschy, J.M., Turley, S.D. & Spady, D.K. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J. Lipid Res. 34, 1637–1659 (1993).
Dietschy, J.M. Central nervous system: cholesterol turnover, brain development and neurodegeneration. Biol. Chem. 390, 287–293 (2009).
Russell, D.W., Halford, R.W., Ramirez, D.M., Shah, R. & Kotti, T. Cholesterol 24-hydroxylase: an enzyme of cholesterol turnover in the brain. Annu. Rev. Biochem. 78, 1017–1040 (2009).
Chen, R.Z., Akbarian, S., Tudor, M. & Jaenisch, R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat. Genet. 27, 327–331 (2001).
Pfrieger, F.W. & Ungerer, N. Cholesterol metabolism in neurons and astrocytes. Prog. Lipid Res. 50, 357–371 (2011).
Xie, C., Lund, E.G., Turley, S.D., Russell, D.W. & Dietschy, J.M. Quantitation of two pathways for cholesterol excretion from the brain in normal mice and mice with neurodegeneration. J. Lipid Res. 44, 1780–1789 (2003).
Ko, M. et al. Cholesterol-mediated neurite outgrowth is differently regulated between cortical and hippocampal neurons. J. Biol. Chem. 280, 42759–42765 (2005).
Jolley, C.D., Dietschy, J.M. & Turley, S.D. Genetic differences in cholesterol absorption in 129/Sv and C57BL/6 mice: effect on cholesterol responsiveness. Am. J. Physiol. 276, G1117–G1124 (1999).
Bellosta, S., Paoletti, R. & Corsini, A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109, III50–III57 (2004).
García-Sabina, A., Gulin-Davila, J., Sempere-Serrano, P., Gonzalez-Juanatey, C. & Martinez-Pacheco, R. Specific considerations on the prescription and therapeutic interchange of statins. Farm. Hosp. 36, 97–108 (2012).
Osterweil, E.K. et al. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 77, 243–250 (2013).
Ardern-Holmes, S.L. & North, K.N. Therapeutics for childhood neurofibromatosis type 1 and type 2. Curr. Treat. Options Neurol. 13, 529–543 (2011).
Keber, R. et al. Mouse knockout of the cholesterogenic cytochrome P450 lanosterol 14α-demethylase (Cyp51) resembles Antley-Bixler syndrome. J. Biol. Chem. 286, 29086–29097 (2011).
Waterham, H.R. Defects of cholesterol biosynthesis. FEBS Lett. 580, 5442–5449 (2006).
Björkhem, I. & Hansson, M. Cerebrotendinous xanthomatosis: an inborn error in bile acid synthesis with defined mutations but still a challenge. Biochem. Biophys. Res. Commun. 396, 46–49 (2010).
Lund, E.G. et al. Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J. Biol. Chem. 278, 22980–22988 (2003).
Lioy, D.T. et al. A role for glia in the progression of Rett's syndrome. Nature 475, 497–500 (2011).
Vance, J.E. Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. Dis. Model. Mech. 5, 746–755 (2012).
Paolicelli, R.C. et al. Synaptic pruning by microglia is necessary for normal brain development. Science 333, 1456–1458 (2011).
Cibičkova, L. Statins and their influence on brain cholesterol. J. Clin. Lipidol. 5, 373–379 (2011).
Stranahan, A.M., Cutler, R.G., Button, C., Telljohann, R. & Mattson, M.P. Diet-induced elevations in serum cholesterol are associated with alterations in hippocampal lipid metabolism and increased oxidative stress. J. Neurochem. 118, 611–615 (2011).
Day, C.P. & James, O.F. Steatohepatitis: a tale of two “hits?”. Gastroenterology 114, 842–845 (1998).
Fyffe, S.L. et al. Deletion of Mecp2 in Sim1-expressing neurons reveals a critical role for MeCP2 in feeding behavior, aggression, and the response to stress. Neuron 59, 947–958 (2008).
Percy, A.K. Rett syndrome: exploring the autism link. Arch. Neurol. 68, 985–989 (2011).
Lyst, M.J. et al. Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT transcriptional co-repressor. Nat. Neurosci. 16, 898–902 (2013).
Ebert, D.H. et al. Activity-dependent phosphorylation of MECP2 threonine 308 regulates interaction with NcoR. Nature published online; doi:10.1038/nature12348 (16 June 2013).
Knutson, S.K. et al. Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO J. 27, 1017–1028 (2008).
Sun, Z. et al. Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration. Nat. Med. 18, 934–942 (2012).
Feng, D. et al. A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science 331, 1315–1319 (2011).
Kile, B.T. et al. Functional genetic analysis of mouse chromosome 11. Nature 425, 81–86 (2003).
McDonald, J.G., Smith, D.D., Stiles, A.R. & Russell, D.W. A comprehensive method for extraction and quantitative analysis of sterols and secosteroids from human plasma. J. Lipid Res. 53, 1399–1409 (2012).
Livak, K.J. & Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔC(T) method. Methods 25, 402–408 (2001).
Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26, 589–595 (2010).
Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
Broman, K.W., Wu, H., Sen, S. & Churchill, G.A. R/qtl: QTL mapping in experimental crosses. Bioinformatics 19, 889–890 (2003).
Acknowledgements
The Genetics Analysis Facility (T. Patton and C. Marshall) at the Centre for Applied Genomics, Toronto Hospital for Sick Kids, Toronto, Ontario, Canada performed the Illumina Goldengate SNP analysis. We thank J. Crowe, M. Schrock, J. Borkey, M. Hill, A. Willis and J. Shaw (Justice laboratory), C. Lee, A. MacKenzie and L. Felker (Shendure laboratory), I. Adams (Katz laboratory), B. Thompson (McDonald and Russell laboratory) and K.S. Posey and A.M. Lopez (Turley laboratory) for technical assistance. We thank C. Spencer and R. Paylor for advice on assessing mouse behavior, which was carried out in the Baylor College of Medicine (BCM) Mouse Neurobehavior Core, and C. Reynolds for advice on plethysmography, which was carried out in the BCM Mouse Phenotyping Core. We thank H. Zoghbi and J. Neul (BCM) for Mecp2 mutant mice. We also thank H. Zoghbi (BCM) and R. Behringer (University of Texas MD Anderson Cancer Center) for valuable discussions during revision of the manuscript. M. Coenraads of the Rett Syndrome Research Trust (RSRT) provided crucial moral and uninterrupted financial support while she aided intellectually through literature searches and advice.
The work was supported by grants from the RSRT, the Rett Syndrome Research Foundation, the International Rett Syndrome Foundation (ANGEL award 2608 to M.J.J. and ANGEL award 2583 to D.M.K.), Autism Science Foundation predoctoral fellowship #11-1015, US National Institutes of Health (NIH) grants NIH T32 GM08307 to C.M.B., NIH U54 GM69338 to D.W.R., NIH R01 HL09610 to S.D.T. and NIH R01 CA115503 to M.J.J. and the National Institute of Neurologic Diseases and Stroke, including funding from the American Recovery and Reinvestment Act (D.M.K.). Grants to the BCM Diabetes and Endocrinology Research Center (2P30DK079638-05) and the BCM Intellectual and Developmental Disabilities Research Center (5P30HD024064-23) from the NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development also supported this work. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health and Human Development or the NIH.
Author information
Authors and Affiliations
Contributions
M.J.J. conceived of the work, carried out the genetic screen and dissected embryos. J.S. and W.H. carried out the capture sequencing and analysis. C.M.B. confirmed map locations and lesions, performed statin injections and carried out behavior and plethysmography testing and quantitative RT-PCR (qRT-PCR). S.M.K. performed protein blotting and liver histopathology. H.M.B. performed preliminary qRT-PCR. J.G.M., B.L. and S.D.T. analyzed sterols and performed synthesis studies. S.D.T. evaluated liver cholesterol and triglycerides. A.A.P. and D.M.K. provided Jaenisch mice and laboratory facilities. D.M.K. helped analyze plethysmography data. M.J.J., D.W.R., D.M.K., S.D.T., S.M.K. and C.M.B. wrote the manuscript with input from the other coauthors.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary figures 1-10 and supplementary tables 1-5 (PDF 6794 kb)
Statin treatment improves home cage activity
30 second videos of mice treated with lovastatin and vehicle at P56 showing an increase in home cage activity in statin treated Mecp2tm1.1Bird/Y mice immediately following removal of the cage lid. (MOV 104247 kb)
Rights and permissions
About this article
Cite this article
Buchovecky, C., Turley, S., Brown, H. et al. A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome. Nat Genet 45, 1013–1020 (2013). https://doi.org/10.1038/ng.2714
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.2714
This article is cited by
-
Genetic Instability and Disease Progression of Indian Rett Syndrome Patients
Molecular Neurobiology (2023)
-
Association of 3-hydroxy-3-methylglutaryl-coenzyme A reductase gene polymorphism with obesity and lipid metabolism in children and adolescents with autism spectrum disorder
Metabolic Brain Disease (2022)
-
Wide spectrum of neuronal and network phenotypes in human stem cell-derived excitatory neurons with Rett syndrome-associated MECP2 mutations
Translational Psychiatry (2022)
-
Sex disparate gut microbiome and metabolome perturbations precede disease progression in a mouse model of Rett syndrome
Communications Biology (2021)
-
Intellectual disability: dendritic anomalies and emerging genetic perspectives
Acta Neuropathologica (2021)